Are there any specific considerations for the dosing and administration of dexmedetomidine in patients with renal or hepatic impairment?

Indunil Karunarathna @Indunil-Karunarathna

09 May 2024 1 2K Report

Are there any specific considerations for the dosing and administration of dexmedetomidine in patients with renal or hepatic impairment?Article Dexmedetomidine: A Comprehensive Review of Pharmacology, Cli...

Indunil Karunarathna

Article Dexmedetomidine: A Comprehensive Review of Pharmacology, Cli...

There are specific considerations for the dosing and administration of dexmedetomidine in patients with renal or hepatic impairment:

Renal Impairment:Dose Adjustment: In patients with renal impairment, particularly those with severe renal dysfunction (e.g., creatinine clearance < 30 mL/min), dexmedetomidine clearance may be reduced. Therefore, dose adjustment is often recommended to avoid drug accumulation and potential adverse effects. Monitoring: Close monitoring of sedation level and vital signs is essential in patients with renal impairment receiving dexmedetomidine. Healthcare providers should assess renal function regularly and adjust the dexmedetomidine dose as necessary based on the patient's renal function and response to therapy. Consideration of Alternatives: In patients with severe renal impairment or end-stage renal disease requiring renal replacement therapy (e.g., hemodialysis), alternative sedative agents with different metabolic pathways or elimination routes may be considered.

Hepatic Impairment:Dose Adjustment: In patients with hepatic impairment, particularly those with severe hepatic dysfunction, dexmedetomidine metabolism and clearance may be impaired. Dose adjustment is often necessary to prevent drug accumulation and potential toxicity. Monitoring: Close monitoring of sedation level, vital signs, and hepatic function is recommended in patients with hepatic impairment receiving dexmedetomidine. Healthcare providers should assess liver function regularly and adjust the dexmedetomidine dose as necessary based on the patient's hepatic function and response to therapy. Consideration of Alternatives: In patients with severe hepatic impairment, alternative sedative agents with minimal hepatic metabolism or with known pharmacokinetic profiles in hepatic dysfunction may be considered.

Special Populations:Elderly Patients: Elderly patients with age-related changes in renal or hepatic function may require dose adjustment or closer monitoring when receiving dexmedetomidine. Pediatric Patients: Dosing and administration of dexmedetomidine in pediatric patients with renal or hepatic impairment should be based on age, weight, and individual patient factors, with consideration given to potential alterations in drug metabolism and clearance.

In summary, patients with renal or hepatic impairment may require dose adjustment and closer monitoring when receiving dexmedetomidine to ensure safe and effective therapy. Healthcare providers should assess renal and hepatic function regularly and adjust the dexmedetomidine dose as necessary based on individual patient factors and response to therapy.

Badges
Science topic

More Indunil Karunarathna's questions See All

Detection and Identification of Amanitins in the Wood-Rotting Fungi Galerina fasciculata andGalerina helvoliceps

Dear all, Can anyone help me to contact the corresponding author of the paper " Muraoka, S., Fukamachi, N., Mizumoto, K., & Shinozawa, T. (1999). Detection and Identification of Amanitins in...

01 January 1970 6,517 3 View

Edible mushrooms and their cultivation

Hi All, Does anyone have the PDF of following book? Chang, S. T.; Miles, P. G. (1989). Edible mushrooms and their cultivation. Edible Mushrooms and Their Cultivation, 345. Thanks

01 January 1970 7,851 1 View

Can two EC50 values with different hill slopes be compared?

Hello, I fit a classical dose response curve Y=Bottom + (Top-Bottom)/(1+10^((LogEC-X)*HillSlope)) to my data (not related to inhibitors etc). The model I use is purely qualitative but it fits...

23 February 2021 8,155 5 View

Is this grounds for theophylline toxicity even though her plasma is within the therapeutic range? if it is, how is that possible?

A patient was given 300 mg Theophylline taken twice a day for the treatment of her bronchial asthma and has a positive clinical response. She has been compliant in taking her medication however,...

09 February 2021 3,489 3 View

Difference between assessing EC50 in presence of physiological levels of human serum albumin and alpha1 acid glycoprotein vs. % human serum?

01 February 2021 1,825 1 View

Can fibrosing cholestatic hepatitis in an immunocompromised patient be diagnosed without a liver biopsy?

provided that all the criteria for diagnosis has been fulfilled and alternative diagnosis are also ruled out. The patient has coagulopathy and transjugular biopsy wont be possible due to resource...

13 January 2021 8,935 4 View

How can we increase awareness about Covid 19 prevention in our city among the local population?

The general public must be made aware of the mode of transmission, presenting symptoms and the measures that can be undertaken to prevent the spread of infection. Few options- Media, Webinars...

03 January 2021 3,538 13 View

Why can I not see any plaques when performing a viral plaque assay with MHV?

28 December 2020 5,515 2 View

Are the receptor proteins on the surface of infected cells will increase or decrease the susceptibility of antivirals?

22 December 2020 3,242 4 View

How to convert Terapeutic Human Doses to Cell Experimentation Doses?

"Toxicological evaluations revealed that Cur is found to be pharmacologically safe, even up to 12 g per day, as reported by several animal studies and in phase-I clinical trials Similarly,...

07 December 2020 3,012 1 View

Why is SV40 not considered an oncogenic virus?

Hello, SV40 is not considered an oncogenic virus in this review:Oncogenic viruses and cancer Why is SV40 not considered an oncogenic virus when it produces the large T antigen, which is...

04 December 2020 8,374 5 View

How to increase presynaptic neurotransmitter release artificially?

I would like to pharmacologically increase presynaptic neurotransmitter release in mice CNS in vivo (through the extracellular micro-infusion of a compound). Which strategy would you recommand?...

02 November 2020 5,645 3 View